| Proportion of pre-RA cases (n = 284) |
---|---|
Research ACPA assay results | |
 Elevateda research ACPA by targeted protein, % | |
  Anti-cit-apolipoprotein A | 2.8 |
  Anti-cit-apolipoprotein E | 8.5 |
  Anti-cit-biglycan | 8.5 |
  Anti-cit-clusterin | 11.7 |
  Anti-cit-enolase | 6.4 |
  Anti-cit-fibrinogen | 19.5 |
  Anti-cit-fibronectin | 7.8 |
  Anti-cit-filaggrin | 8.9 |
  Anti-cit-histone 2A | 12.8 |
  Anti-cit-histone 2B | 8.9 |
  Anti-cit-vimentin | 14.9 |
 CCP (research) | 15.6 |
 Any research ACPA+ or CCP+ (sensitive), % | 30.1 |
 ≥2 research ACPA+ or CCP+ (specific), % | 20.2 |
Commercial CCP2 assay results | |
 CCP2 >3 units/mL (sensitive cutpoint), % | 30.4 |
 CCP2 >5 units/mL (clinical cutpoint), % | 23.8 |
Definitions of ACPA positivity | |
 Primary/sensitive: any research ACPA+ or CCP2 >3 units/mL, % | 33.8 |
 Secondary/specific: ≥2 research ACPA+ or CCP2 >5 units/mL, % | 21.1 |